We are developing cytokine fusion molecules and antibodies that target immune cells relevant to a range of cancers. Of particular focus are cancers of the digestive tract, such as gastric, esophageal, pancreatic, and liver cancers. We believe there are applications for stimulating T-cells that are relevant to other cancers, as well.
We are also developing cytokine fusion molecules for addressing autoimmune diseases and inflammation disorders. Our prodrug candidates are focused on selectively stimulating specific subsets of immune cells to treat diseases such as lupus, inflammatory bowel disease (IBD), and Type 1 diabetes.
ASKG712 is a bifunctional molecule that targets vascular endothelial growth factor (VEGF) and Ang-2 to address specific needs in ophthalmology, including wet age-related macular degeneration (wAMD) and diabetic macular edema (DME ).
* Biosimilar program, out-licensed
** Masked or prodrug